Targeting NRAS-Derived Public Neoantigens in T Cell-Based Cancer Immunotherapy 2261145
T cells mediate anti-cancer immune responses through recognition of neoantigens - cancer-specific, mutation-derived peptides presented by MHC proteins. “Public” neoantigens are a subset of neoantigens derived from recurrently mutated driver genes and presented by common HLA alleles, making them ideal immunotherap...